Featuring a slide presentation from Dr Julia Rotow, including the following topics:

• Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)
• Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)
• Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)
• Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)
• Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)
• Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)
• Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)

CME information and select publications

Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• EGFR Mutations (2:23)
• HER2 Alterations (22:40)
• Available and Investigational Immunotherapies (32:14)
• Small Cell Lung Cancer (40:48)

CME information and select publications

Featuring an interview with Dr Alexander E Drilon, including the following topics:

• Overview of targetable biomarkers in lung cancer (0:00)
• Biomarker testing for genomic alterations in lung cancer (5:24)
• Overview of ROS1 alterations in lung cancer (13:44)
• Efficacy data with ROS1 inhibitors for lung cancer (17:02)
• Safety data with ROS1 inhibitors for lung cancer (21:15)
• Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)
• Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)
• Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)

NCPD information and select publications

Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics:

• Introduction (0:00)
• Best Option for Your Patient (1:28)
• Biological Considerations (6:26)
• KRAS G12C Inhibitors (11:33)
• Second-Line Treatment (13:02)
• Current Clinical Trials in the First-Line Metastatic Setting (32:18)
• Current Clinical Trials in the Localized Setting (49:52)
• Current Clinical Trials with New Treatment Combinations and Agents (53:51)

CME information and select publications

Featuring an interview with Prof Ticiana Leal, including the following topics:

• Pathophysiology and clinical signs and symptoms (0:00)
• Screening and/or diagnostic approaches (5:45)
• Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36)
• Key clinical trial data for amifampridine and practicalities of its administration (14:05)
• Building awareness among patients, caregivers and the oncology community (22:37)
• Role of pyridostigmine in managing Lambert-Eaton myasthenic syndrome (LEMS); potential integration of EMG (electromyography) into monitoring (25:35)
• Case: A man in his early 70s who receives a diagnosis of limited-stage SCLC (LS-SCLC) with LEMS and undergoes treatment (27:41)
• Case: A woman in her late 70s already diagnosed with LS-SCLC who is subsequently evaluated and treated for LEMS (37:55)
• Current research and potential developments in the treatment of SCLC (48:32)

CME information and select publications

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics:

• Introduction (0:00)
• Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17)
• Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24)
• Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28)
• Management of Limited-Stage SCLC — Dr Ganti (1:31:54)

CME information and select publications

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:

• Introduction: Relative Impact of Targeted Treatment (00:00)
• HER2 Alterations (8:04)
• KRAS Mutations (24:25)
• MET Overexpression (30:34)
• ALK Fusions (32:34)
• ROS1 Fusions (42:36)
• RET Fusions (52:00)

CME information and select publications

Featuring perspectives from Dr Joshua K Sabari, including the following topics:

• Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00)
• Heymach JV et al. Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study. ESMO 2025;Abstract 2020P. (8:30)
• Schram AM et al. Beamion PANTUMOR-1: Rationale and design of a phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncol 2026;22(7):795-803. (12:53)
• Johnson ML et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. ASCO 2024;Abstract TPS8654. (19:40)
• Le X et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. ASCO 2025;Abstract TPS8648. (21:41)
• Li BT et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). ASCO 2022;Abstract TPS9137. (22:59)
• Jänne PA et al. Trastuzumab deruxtecan for ERBB2-mutant metastatic NSCLC with or without brain metastases: A secondary analysis of randomized clinical trials. JAMA Netw Open 2025;8(11):e2543107. (24:37)

CME information and select publications